Navigation Links
Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency
Date:9/21/2009

EMERYVILLE, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced that on September 15, 2009, the company received a letter from NASDAQ stating that, for the last 30 consecutive business days, the bid price of its common stock has closed below the minimum $1.00 per share requirement for continued listing on the NASDAQ Capital Market. The letter further stated that the company has been provided a period of 180 calendar days, or until March 15, 2010, to regain compliance. If, at anytime before March 15, 2010, the bid price of the common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, NASDAQ has indicated that it will provide written notification that compliance has been regained.

The deficiency letter has no effect on the listing of the company's common stock at this time and its common stock will continue to trade on the NASDAQ Capital Market under the symbol "BNVI."

In the event the Company does not regain compliance with the rule prior to the expiration of the period, it will receive written notification that its securities are subject to delisting. Alternatively, the Company may be eligible for an additional grace period if it meets the initial listing standards, with exception of bid price, for the NASDAQ Capital Market. If it meets the initial listing criteria, NASDAQ staff will notify the Company that it has been granted an additional 180 calendar day compliance period.

Bionovo intends to use its best efforts to regain compliance with NASDAQ's minimum bid requirement.

For further information on the relevant NASDAQ rules, please consult NASDAQ Listing Rules 5550(a)(2) - bid price, 5810(c)(3)(A) - grace period, 5810(b) - public disclosure, and 5505 - Ca
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community
2. Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer
3. Bionovo to Present at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference
4. Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer - All Claims Denied
5. Bionovo, Inc. to Announce First Quarter Fiscal Year 2009 Financial Results on Thursday, May 7, 2009
6. Bionovo to Present at the Cambria Capital Investor Meeting
7. Bionovo to Present at Wall Street Analyst Forums 20th Annual Institutional Investor Conference
8. Bionovo, Inc. to Announce Fourth Quarter and Year-End Financial Results on Thursday, March 12, 2009
9. Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovos Scientific Advisory Board
10. Bionovo Announces Presentation at the National Cancer Institute
11. Bionovo Announces Cost Control Measures Taken

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2009)... World Famous Lasik surgeo...k surgery to an ART in his pursuit for vision beyo...es an international clientel and is widely publish... Jacksonville, FL (PRWEB) November ...nstitute has been selected by Goldline Research a...
(Date:11/22/2009)... NEW YORK (Nov. 22 2009) -- Physician-scientists f...a molecular mechanism that may prove to be a power...homa, a type of cancer that affects lymphocytes, o... researchers have been able to powerfully suppress...ls. , Promising results have led to the design o...
(Date:11/22/2009)... HealthSmart, an innovativ...unced that it has successfully completed a recapit...Company’s other lenders. Silver Point Capit...enwich, Connecticut. This recapitalization allows...its business strategy. , , ...
(Date:11/22/2009)..., , WASHINGTON, Nov. 21 /PRNewswire-USNewswir...ollowing statement upon the United States Senate,s...ealth Care legislation: ,, "Senators Arlen Spec...ians and all Pennsylvanians for casting stand-up, ...sident Obama,s historic Affordable Health Care Ref...
(Date:11/21/2009)..., , "This bill provides for an unpreced... is health care about if it is not for preserving ...ded, it must be defeated." Charmaine Yoest ,...mericans United for Life Action President and CEO ... the Senate by releasing the following statement: ...
Breaking Medicine News(10 mins):Health News:Dr. Arun Gulani Listed in Forbes Magazine as One of The Leading Laser Eye Surgeons of the United States 2Health News:New cancer target for non-Hodgkin's lymphoma 2Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2
...HINGTON (30 May 2008) -- Legislation that IEEE-USA...ination in employment and health insurance based o.... , The Genetic Information Nondiscrimination Act...appreciation in a letter ( http://www.ieeeusa.org/...
...el Votes, 16-0, in Favor of Short-Term Treatment o...), CHICAGO, May 30 GlaxoSmithKline (NYSE: GSK )...rug Administration,s,Oncology Drugs Advisory Commi...ents with chronic idiopathic,thrombocytopenic purp...
... prevalence of pre-cancerous masses in the colon i... 49 years of age and those who are 50 to 59 years ... the official journal of the American Gastroentero...easing incidence of colon cancer at that age. Beca...
...RK, May 30 We know the damage the sun can do to,o...damaging rays?, Listen to this report from Transi...R.aspx?story=35173 , Registered journalists can a...aphics and,photos for free and unrestricted use at...
..., Calif., May 30 Edwards Lifesciences,Corporation...nologies to,treat advanced cardiovascular disease,...ons from the U.S. Food and Drug Administration (FD...pertain to preclinical bench testing and the clari...
...HESTER, Minn. -- Mayo Clinic researchers have deve...f two prominent tumor suppressor genes, p16 and p1... these genes were expressed at increased levels as...ging, while p19 stops that process. , The finding...
Other Medicine News:Health News:IEEE-USA-supported Genetic Information Nondiscrimination Act signed into law 2Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 2Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 3Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 4Health News:Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s 2Health News:Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s 3Health News:Edwards Lifesciences Receives Additional Questions From the FDA About the LifeStent Product Line 2
(Date:11/21/2009)..., , WASHINGTON, Nov. 21 An ur...ectious diseases in the developing world has promp...mic researchers, non-profit product development pa...ology companies. As noted today in a symposium at ... Tropical Medicine and Hygiene (ASTMH), these coll...
(Date:11/20/2009)..., , CARY, N.C., Nov. 20 /PRNewswire-FirstCa...X ), a specialty pharmaceutical company focused on...cant products primarily for the respiratory and re... a Warning Letter from the Food and Drug Administr...le tablets (Phenylephrine HCl 10 mg, Pyrilamine Ma...
(Date:11/20/2009)..., , HARRISBURG, Pa., Nov. 20 /PRNewswire-U... providing free H1N1 flu shots to members of prior...e vaccine. ,, A total of 18 clinics are being h... are from 2 p.m. to 8 p.m. Hours on Saturday, Nov....the clinics will operate from 2 p.m. to 8 p.m. ,...
Breaking Medicine Technology:ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 2ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 3Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 2Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 3Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2Fate Therapeutics announces creation of small molecule platform for commercial scale reprogramming 10409 1Fate Therapeutics announces creation of small molecule platform for commercial scale reprogramming 10409 2Project Runway Designer in Philadelphia for AIDS Walk Philly to Educate About Living with HIV through Living Positive By Design 59703 1Project Runway Designer in Philadelphia for AIDS Walk Philly to Educate About Living with HIV through Living Positive By Design 59703 2Project Runway Designer in Philadelphia for AIDS Walk Philly to Educate About Living with HIV through Living Positive By Design 59703 3Florida Celebrates National Healthcare Quality Week 59698 1Florida Celebrates National Healthcare Quality Week 59698 2
...ANDS, Texas--(BUSINESS WIRE)--Jun 21, 2007 - Opexa...ved in the,development and commercialization of ce...ta in an open-label Phase I/II,extension clinical ...in(TM), for multiple sclerosis (MS). In this one-y...ng remitting (RRMS),and secondary progressive (SPM...
...ISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun ...-based non-profit,pharmaceutical company, today an... approved drug product, Paromomycin IM,Injection (...f The,New England Journal of Medicine (NEJM). This...n is safe, effective, and well suited,to curing vi...
Other Medicine Technology:Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 2Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 3Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 4Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 5Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 2Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 3Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 4
...nlike any trocar system you've ever seen., ,The O...ms in one designed to be versatile, operationally...eeds., ,By offering options in disposability and ...effectively address the individual preferences of ...
ENDOPATH Surgical Thoracic Trocar Sleeve with Rounded Tip Obturator
MultAcoice™ Metzenbaum Curved Scissors
MultAcoice™ Dissecting Scissors
Medicine Products: